EVAX

Evaxion Biotech

1.85 USD
-0.02
1.07%
At close Mar 18, 4:00 PM EDT
After hours
1.90
+0.05
2.70%
1 day
-1.07%
5 days
-5.13%
1 month
-28.85%
3 months
-91.59%
6 months
-97.63%
Year to date
-91.99%
1 year
-97.60%
5 years
-99.93%
10 years
-99.93%
 

About: Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Employees: 49

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

25% more funds holding

Funds holding: 8 [Q3] → 10 (+2) [Q4]

0.46% more ownership

Funds ownership: 0.99% [Q3] → 1.45% (+0.46%) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

60% less capital invested

Capital invested by funds: $1.71M [Q3] → $682K (-$1.03M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$6
224%
upside
Avg. target
$10
441%
upside
High target
$14
657%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
23% 1-year accuracy
46 / 200 met price target
657%upside
$14
Buy
Reiterated
20 Feb 2025
Lake Street
Thomas Flaten
44% 1-year accuracy
4 / 9 met price target
224%upside
$6
Buy
Maintained
4 Feb 2025

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will further enhance the data package from its ongoing phase 2 trial with the company's lead asset EVX-01 by extending the trial from two to three years. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine being developed as a treatment for advanced melanoma (skin cancer).
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
Neutral
GlobeNewsWire
1 month ago
Evaxion announces closing of $10.8 million public offering
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs.
Evaxion announces closing of $10.8 million public offering
Neutral
GlobeNewsWire
1 month ago
Evaxion announces pricing of $10.8 million public offering
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs.
Evaxion announces pricing of $10.8 million public offering
Neutral
GlobeNewsWire
1 month ago
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
COPENHAGEN, Denmark, January 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received notice from the Nasdaq Stock Market LLC (“Nasdaq”) that it has been granted a 180-day extension to comply with Nasdaq's minimum stockholder's equity requirement. Meanwhile, Evaxion has already restored its equity above the Nasdaq minimum requirement.
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
Neutral
GlobeNewsWire
2 months ago
Evaxion announces completion of ADS ratio change
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.
Evaxion announces completion of ADS ratio change
Neutral
GlobeNewsWire
2 months ago
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”).
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
Neutral
GlobeNewsWire
2 months ago
Evaxion announces plan to implement ADS ratio change
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”). The ADS ratio change is expected to become effective on or about January 13, 2025, U.S. Eastern Time (the “effective date”).
Evaxion announces plan to implement ADS ratio change
Neutral
GlobeNewsWire
4 months ago
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. The data will be presented today at the 9th International Conference on Vaccines Research & Development, taking place in Boston, USA.
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
Neutral
GlobeNewsWire
4 months ago
Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results.
Evaxion announces business update and third quarter 2024 financial results
Neutral
GlobeNewsWire
4 months ago
Evaxion to announce business update and third quarter 2024 financial results on October 31
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.
Evaxion to announce business update and third quarter 2024 financial results on October 31
Charts implemented using Lightweight Charts™